• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥司他韦给药途径影响危重症患儿代谢物浓度。

Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children.

机构信息

From the Division of Hospital Medicine, Department of Pediatrics.

Division of Clinical Pharmacology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

出版信息

Pediatr Infect Dis J. 2019 Dec;38(12):1224-1227. doi: 10.1097/INF.0000000000002473.

DOI:10.1097/INF.0000000000002473
PMID:31738337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7023915/
Abstract

We performed a prospective cohort study to investigate oseltamivir administration in critically ill children. We found that enteric tube administration of oseltamivir resulted in lower concentrations of its active metabolite compared with oral delivery. These findings could have significant clinical implications, and more studies are required to better understand the effects of administration route on potential lower systemic metabolite exposure.

摘要

我们进行了一项前瞻性队列研究,调查了重症儿童中奥司他韦的给药情况。我们发现,与口服给药相比,奥司他韦的肠内管给药导致其活性代谢物的浓度降低。这些发现可能具有重要的临床意义,需要更多的研究来更好地了解给药途径对潜在全身代谢物暴露降低的影响。

相似文献

1
Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children.奥司他韦给药途径影响危重症患儿代谢物浓度。
Pediatr Infect Dis J. 2019 Dec;38(12):1224-1227. doi: 10.1097/INF.0000000000002473.
2
Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique.羧基奥司他韦在重症患者中的药代动力学:每个患者都是独特的。
Intensive Care Med. 2013 May;39(5):977-8. doi: 10.1007/s00134-013-2851-x. Epub 2013 Feb 27.
3
High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.重症监护病房危重症儿童经鼻胃管给予奥司他韦羧酸盐后血浆浓度高且安全。
Antimicrob Agents Chemother. 2011 Jan;55(1):433-5. doi: 10.1128/AAC.00813-10. Epub 2010 Oct 11.
4
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.重症患者接受连续静脉-静脉血液透析和/或体外膜氧合时奥司他韦和奥司他韦羧酸的药代动力学。
Pharmacotherapy. 2012 Dec;32(12):1061-9. doi: 10.1002/phar.1151.
5
Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.开放标签研究中静脉注射奥司他韦在婴幼儿和儿童中的药代动力学及安全性
Int J Clin Pharmacol Ther. 2015 Jul;53(7):531-40. doi: 10.5414/CP202307.
6
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.用于治疗儿童流感的口服奥司他韦混悬液的药代动力学及剂量推荐
Paediatr Drugs. 2001;3(3):229-36. doi: 10.2165/00128072-200103030-00005.
7
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.早期奥司他韦治疗对 2009 年甲型流感危重症患者结局的影响。
J Antimicrob Chemother. 2011 May;66(5):1140-9. doi: 10.1093/jac/dkq511. Epub 2011 Jan 7.
8
Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.接受体外膜肺氧合支持的危重症成年患者中奥司他韦的药代动力学
Anaesth Intensive Care. 2013 Jan;41(1):66-73. doi: 10.1177/0310057X1304100112.
9
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.重症甲型 H1N1 流感患者奥司他韦的肠内吸收和药代动力学。
CMAJ. 2010 Mar 9;182(4):357-63. doi: 10.1503/cmaj.092127. Epub 2010 Feb 16.
10
A part-randomized study of intravenous oseltamivir in adolescents and adults.青少年和成人静脉注射奥司他韦的部分随机研究。
Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1181-8. doi: 10.1007/s10096-015-2338-5. Epub 2015 Feb 13.

引用本文的文献

1
Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials.药代动力学和药效学原理:新生儿临床试验优化设计的独特考量
Front Pediatr. 2024 Jan 12;11:1345969. doi: 10.3389/fped.2023.1345969. eCollection 2023.
2
Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.在危重症儿童的β-内酰胺类抗生素药代动力学研究中,机会性采样方法具有可行性。
J Clin Pharmacol. 2021 Apr;61(4):565-573. doi: 10.1002/jcph.1773. Epub 2020 Oct 27.
3
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.

本文引用的文献

1
Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009-2014.2009-2014 年加拿大安大略省因实验室确诊流感或呼吸道合胞病毒而住院的婴幼儿的特征和结局。
Pediatr Infect Dis J. 2019 Apr;38(4):362-369. doi: 10.1097/INF.0000000000002164.
2
Influenza-Associated Pediatric Deaths in the United States, 2010-2016.美国 2010-2016 年与流感相关的儿科死亡病例。
Pediatrics. 2018 Apr;141(4). doi: 10.1542/peds.2017-2918. Epub 2018 Feb 12.
3
Neuraminidase inhibitors for critically ill children with influenza.
COVID-19 重症患者中法匹拉韦的药代动力学。
Clin Transl Sci. 2020 Sep;13(5):880-885. doi: 10.1111/cts.12827. Epub 2020 Jun 29.
神经氨酸酶抑制剂治疗流感危重症儿童。
Pediatrics. 2013 Dec;132(6):e1539-45. doi: 10.1542/peds.2013-2149. Epub 2013 Nov 25.
4
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.奥司他韦的群体药代动力学:儿科到老年医学。
Antimicrob Agents Chemother. 2013 Aug;57(8):3470-7. doi: 10.1128/AAC.02438-12. Epub 2013 May 13.
5
High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.重症监护病房危重症儿童经鼻胃管给予奥司他韦羧酸盐后血浆浓度高且安全。
Antimicrob Agents Chemother. 2011 Jan;55(1):433-5. doi: 10.1128/AAC.00813-10. Epub 2010 Oct 11.
6
Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.体外膜肺氧合支持下危重症儿童的奥司他韦和奥司他韦羧酸血浆浓度。
PLoS One. 2010 Jun 3;5(6):e10938. doi: 10.1371/journal.pone.0010938.
7
Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.白细胞介素-6通过抑制羧酸酯酶HCE1和HCE2的表达,改变细胞对氯吡格雷、伊立替康和奥司他韦的反应性。
Mol Pharmacol. 2007 Sep;72(3):686-94. doi: 10.1124/mol.107.036889. Epub 2007 May 30.
8
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.用于治疗儿童流感的口服奥司他韦混悬液的药代动力学及剂量推荐
Paediatr Drugs. 2001;3(3):229-36. doi: 10.2165/00128072-200103030-00005.
9
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.前体药物奥司他韦及其活性代谢产物Ro 64-0802的临床药代动力学
Clin Pharmacokinet. 1999 Dec;37(6):471-84. doi: 10.2165/00003088-199937060-00003.
10
MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.
Comput Biol Med. 1992 May;22(3):155-63. doi: 10.1016/0010-4825(92)90011-b.